Company news
Aditxt, Inc. news in 2021
Aditxt, Inc.'s news releases, calls and decks from 2021, newest first.
Aditxt Signs Amendment to Extend Worldwide Licensing Agreement, Granting Exclusivity in all Fields of Use
December 28, 2021
Aditxt Signs Share Exchange Agreement to Acquire AiPharma
December 27, 2021
Aditxt, Inc. Signs Non-Binding Letter of Intent to Acquire Point-of-Care Diagnostic Technology Development Company
December 12, 2021
Aditxt Announces Closing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants
December 5, 2021
Aditxt Extends the Timeline to Sign the Definitive Agreement to Acquire AiPharma Global to December 16, 2021
December 1, 2021
Aditxt Announces Pricing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants Led by Leading Healthcare Investor
November 30, 2021
Aditxt Announces Proposed Public Offering of Common Stock and Warrants
November 29, 2021
Aditxt Provides an Update Regarding its Target Acquisition AiPharma Global Holdings LLC
November 11, 2021
Aditxt Partners With CLX Health to Offer AditxtScore™ for COVID-19 Immune Monitoring Service Through CLX’s TrustAssure™ Platform
November 2, 2021
Aditxt Announces Closing of $4.25 Million Public Offering
October 19, 2021
Aditxt Announces Pricing of $4.25 Million Public Offering
October 17, 2021
Aditxt Signs a Transaction Agreement to Acquire AiPharma, Rights Holder of Antiviral Tablet Avigan/Reeqonus/Qifenda Used in the Treatment of Over 1.5 Million COVID-19 Patients Outside the U.S. and Canada
October 4, 2021
Aditxt Appoints Corinne Pankovcin as President and Thomas J. Farley as Chief Financial Officer as Company Prepares for Global Commercialization
September 26, 2021
Aditxt, Inc. and SphereDX Launch AditxtScore™ for COVID-19 in Kentucky, Ohio and Indiana to Address Individual Immune Status Uncertainty and Help Evaluate Cadence for Booster Shots
September 8, 2021
Aditxt Announces Closing of $11 Million Registered Direct Offering, and Funding of Bridge Loan Satisfying a Key Term of its Letter of Intent for Planned Acquisition of Commercial Stage Pharma Company with Anti-Viral COVID-19 Therapy
September 6, 2021
Aditxt Announces Pricing of $11.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
August 25, 2021
Aditxt, Inc. Signs Letter of Intent for Exclusive Rights to Negotiate the Acquisition of a Biopharmaceutical Company Commercializing and Distributing Antiviral Oral Therapy for COVID-19
August 24, 2021
Aditxt, Inc. and Great Lakes Medical Laboratory Launch AditxtScore for COVID-19 in State of Michigan as a Personalized Approach to Addressing COVID-19 Pandemic
August 10, 2021
Aditxt Provides Update on AditxtReprogramming’s™ Apoptotic DNA Immunotherapy Therapeutic Platform
August 3, 2021
Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19
July 11, 2021
Aditxt Opens its First High-Capacity Immune Monitoring Center in Richmond, VA
July 6, 2021
Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors
June 17, 2021
Aditxt Signs Channel Partner Agreement with Meridian HSN to Make AditxtScore™ for COVID-19 Available to its Network of Healthcare Provider Partners
May 5, 2021
Aditxt to Establish State-of-the-Art Immune Monitoring Center in Richmond, VA
May 2, 2021
Aditxt Therapeutics Names Sunny Uberoi as its first Chief Communications Officer
April 12, 2021
HealthBar Becomes AditxtScore™ Channel Partner to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring to Complement its Concierge and Drive-Thru Testing Services
April 5, 2021
Collection Sites, LLC Named AditxtScore™ Channel Partner to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring Through Its Mobile Testing Centres
March 31, 2021
Immunologist and Clinical Transplant Expert, Dolly B. Tyan, PhD, Joins Aditxt as Senior VP of Clinical Development - Transplantation
January 28, 2021
Aditxt Secures $5 Million Financing to Scale AditxtScore™ Operational Capacity
January 25, 2021
AditxtScore™ Immune Monitoring Service Will be Operational on February 1st
January 20, 2021